Slide 1: Q2 2025 Earnings Call
Q2 2025 Earnings Call August 6, 2025
Slide 2: Safe harbor disclosures
Safe harbor disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact could be deemed forward-looking. These forward-looking statem
Slide 3: Q2 2025 highlights
Q2 2025 highlights $4.1M Q2 2025 revenue Launched high-throughput Proteograph ONE workflow, enabling unprecedented scale and efficiency Announced multiple population-scale studies leveraging Proteograph Product Suite ~$263M Strong quarter for instrument placements and Cash, cash equivalents, third-p
Slide 4: Redefining deep, unbiased proteomics with the launch of new Proteograph ONE workflow
Drive Innovation Redefining deep, unbiased proteomics with the launch of new Proteograph ONE workflow Identify 10x More protein groups than direct (neat) methods served Analyze 1,000+ Samples per week with the Doubles throughput to 80 samples per run, with ~30% reduction Proteograph ONE workflow in
Slide 5: Changing the arc of proteomics by enabling deep, unbiased population-scale studies
Validate Platform Changing the arc of proteomics by enabling deep, unbiased population-scale studies First-of-its-kind 20,000-sample proteomics study in partnership with Korea University Powered by new Proteograph ONE workflow and Thermo Fisher Scientific’s Orbitrap Astral mass spectrometer 10,000-s
Slide 6: Evidence is scaling as Proteograph adoption grows
Validate Platform Evidence is scaling as Proteograph adoption grows Growing validation of Cumulative peer-reviewed Researchers demonstrated platform makes us a trusted publications differentiated Proteograph partner for customers insights at June conferences 52 customer publications, 2025 52 America
Slide 7: Novel proteins identified with the Proteograph ONE offer new insights into metabolic disease research
Validate Platform Novel proteins identified with the Proteograph ONE offer new insights into metabolic disease research Metabolically healthy obese individuals may Potential benefit Protein Buffer oxidative stress better Glutathione Peroxidase 3 Regulate glucose levels better Insulin-Like Growth Fac
Slide 8: Drs. Lagenberg and Pietzner demonstrate the unique value of Seer data in the Genes & Health cohort
Validate Platform Drs. Lagenberg and Pietzner demonstrate the unique value of Seer data in the Genes & Health cohort Seer detected a high number of proteins previously not found by affinity-based technologies Seer detected a high number of pQTLs that were previously not found by affinity-based techn
Slide 9: Accelerating access to the Proteograph
Enhance Access Accelerating access to the Proteograph Strong demand for Operationalizing the co-marketing STAC services and sales agreement Over half of instrument shipments in Q2 Completed training of Thermo Fisher US and 2025 were acquired by customers who Europe sales teams had previously accesse
Slide 10: Q2 2025 financial overview
Q2 2025 financial overview Q2’25 Q2’24 Revenue $4.1M $3.1M ~$263M Product & Service Revenue $3.5M $2.4M Cash, cash equivalents and investments, no debt1 Related Party Revenue $0.4M $0.6M Other Revenue $0.1M $0.0M Gross Margin 52% 56% ~3.9M shares Operating Expenses $22.6M $28.8M repurchased in Q2 St
Slide 11: Reiterating full year 2025 revenue guidance
Reiterating full year 2025 revenue guidance $17M - $18M 24% y/y growth at midpoint 11 © 2025 Seer, Inc.
Slide 12: Growth Catalysts
2025 External validation of unique + actionable biological insights Drive larger cohort studies Revenue growth Continuing to drive innovation Growth Catalysts Expand user base, continue to enhance access 12 © 2025 Seer, Inc.
Slide 13: Slide 13